Description
Enzalutamide, marketed under the brand name XTANDI, It is an prescription medication that has been approved by the FDA for multiple uses, including:
Metastatic castration-sensitive prostate cancer (mCSPC): Approved on December 16, 2019, based on the ARCHES trial
Non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis: Approved on November 16, 2023, based on the EMBARK trial
Castration-resistant prostate cancer: Previously approved by the FDA
What is XTANDI (Enzalutamide) ?
XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer and nonmetastatic castration-resistant prostate cancer.
How to order approved “XTANDI (Enzalutamide) for capsules” Medicine?
XTANDI (Enzalutamide) Capsules is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing XTANDI and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
